BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 1, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld

BioWorld
BioWorld RSS Feed RSS

Vial and syringe with blue hues

Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift

Dec. 5, 2025
By Randy Osborne
No Comments
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for Immunization Practices (ACIP) meeting, which took up – again – the matter of hepatitis B virus (HBV) vaccine scheduling, a day after the panel voted not to vote on such guidance.
Read More

Biopharma money raised by quarter in 2025 (US$M)

Dec. 5, 2025
Biopharma money raised to-date and by month in 2025, including public, private and other financings.
Read More

ACIP continues to struggle with HBV vaccine scheduling

Dec. 5, 2025
No Comments
A preview of the next edition of BioWorld, Dec. 5, 2025
Read More
Illustration of chromosome unraveling down to the DNA
Drug design, drug delivery & technologies

First phase of synthetic human genome project successfully completes

Dec. 5, 2025
By Nuala Moran
No Comments
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a multistep method for transfecting mouse stem cells with native human chromosomes, where they are stably maintained and can be manipulated to replace native DNA with synthetic DNA. The engineered chromosomes can then be transferred into a human cell in place of the native chromosomes.
Read More

Regulatory actions for Dec. 4, 2025

Dec. 4, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Aobiome, Celltrion, Polypid.
Read More

Other news to note for Dec. 4, 2025

Dec. 4, 2025
Biopharma happenings, including deals and partnerships, and other news in brief: BCM, Biontech, Curevac, Corrixr, Formosa, Inhatarget, Iolyx, Merxin, Rxilient, Vaximm.
Read More

In the clinic for Dec. 4, 2025

Dec. 4, 2025
Clinical updates, including data readouts and publications: ADC, Biogen, Black Diamond, BMS, Capricor, Clene, Eisai, Elevar, Iliad, Lantern, Muvon, Nuvation, Onco3r, Oncotelic, Pharvaris, Quadriga.
Read More

Financings for Dec. 4, 2025

Dec. 4, 2025
Biopharmas raising money in public or private financings, including: Auxilius, Iolyx, Junevity, Triana.
Read More

Appointments and advancements for Dec. 4, 2025

Dec. 4, 2025
New hires and promotions in the biopharma industry, including: Actithera, Biocardia, Dimerx, March, Realta, Thryv.
Read More
3D Euro symbol
Newco news

Laigo raises €11.5M seed money for targeted protein degradation

Dec. 4, 2025
By Nuala Moran
No Comments
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.
Read More
Previous 1 2 … 173 174 175 176 177 178 179 180 181 … 9111 9112 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Digital brain and silhouette

    Will Ovid’s golden age of KCC2 metamorph CNS?

    BioWorld
    The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing